Daclizumab: outcome of phase III trials and mechanism of action
Author:
Publisher
Elsevier BV
Subject
Transplantation,Surgery
Reference5 articles.
1. Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts
2. A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL ANTIBODY IN HUMAN RENAL TRANSPLANTATION
3. A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION
4. A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeted Molecular Therapy for Ovarian Cancer Patients;Advances in Diagnosis and Management of Ovarian Cancer;2022
2. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes;Transplant International;2015-04-21
3. A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation;Transplantation Research;2014-07-30
4. Induction Immunosuppressive Therapy;Textbook of Organ Transplantation;2014-07-25
5. Targeted Molecular Therapy for Patients with Ovarian Cancer;Advances in Diagnosis and Management of Ovarian Cancer;2013-10-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3